Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $15.77 billion market cap company with an "Excellent" financial health rating according to InvestingPro, executed a ...

On Friday, doctors at Massachusetts General Hospital announced that a 66-year-old New Hampshire man had successfully received ...

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

United Therapeutics is pioneering a new frontier in organ transplants using pig kidneys. STORY HIGHLIGHTS FDA clears United Therapeutics for human trials of pig-to-human kidney transplants.

Corporation (NASDAQ: UTHR) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a pioneering clinical trial of its gene-edited xenotransplantation kidney, named UKidney, ...

The U.S. Food and Drug Administration has approved the first-ever clinical trials testing pig kidney transplants in people ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...

The second person ever has received a transplant with a genetically modified pig kidney.

Mass General Brigham has announced the successful completion of another gene-edited pig kidney transplant, the first of a ...

It's as significant for the medical community as it is for the local business. Silver Spring’s United Therapeutics Corp. (NASDAQ: UTHR) has scored a regulatory green light to start clinical ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...